Literature DB >> 16818006

Surgical wait times for patients with urological cancers: a survey of Canadian surgeons.

Neil Fleshner1, George Dranitsaris, Antonio Finelli, John Tsihlias, David Bell, Martin Gleave.   

Abstract

BACKGROUND: The wait times for urological cancer surgeries in Canada has increased over the past 2 decades. This is of concern to patients, physicians and other key stakeholders because there is evidence that delaying surgery beyond a recommended threshold could have a negative impact on clinical outcomes. To address these trends, a Canadian surgical wait times (SWAT) initiative has been undertaken to develop a consensus document and make recommendations on appropriate wait times. As a first step, the SWAT steering committee determined that current wait times estimates were required for the four key disease sites; prostate, bladder, kidney and testes. To obtain such data, a survey of Canadian urological surgeons was undertaken.
METHODS: A structured electronic mailing strategy was adopted as recommended by Dillman (1978). Standardized data collection forms were sent to members of the Canadian Urological Association (CUA) and attendees to the 2005 CUA meeting. Survey items consisted of respondent demographic data, information on surgical wait times for the four key disease sites and potential barriers to timely cancer surgery.
RESULTS: One hundred and five urological surgeons responded to the survey. There was considerable variation in wait times between and within the four disease sites with bladder and kidney cancer surgeries displaying the widest range. Operating room availability and staging tests were identified as the most significant barriers to efficient cancer surgery.
CONCLUSIONS: The wide variation in wait times identified in this study suggest that the overall time to treatment from referral is beyond the duration considered by many experts and by the Canadian Society of Surgical Oncology to be acceptable. These issues need to be addressed through a partnership between the key stakeholders in order to reduce the potentially negative impact on clinical outcomes and patient quality of life.

Entities:  

Mesh:

Year:  2006        PMID: 16818006

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  6 in total

1.  Wait times: not the only indicator of performance.

Authors:  Armen Aprikian
Journal:  Can Urol Assoc J       Date:  2008-12       Impact factor: 1.862

2.  Factors affecting surgical wait times for breast reconstruction.

Authors:  Kirsty U Boyd; Claire Lf Temple; Douglas C Ross
Journal:  Can J Plast Surg       Date:  2010

3.  Urologist referral delay and its impact on survival after radical cystectomy for bladder cancer.

Authors:  F Santos; A Dragomir; W Kassouf; E Franco; A Aprikian
Journal:  Curr Oncol       Date:  2015-02       Impact factor: 3.677

4.  Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada.

Authors:  Michael Metcalfe; Wassim Kassouf; Ricardo Rendon; David Bell; Jonathan Izawa; Joseph Chin; Anil Kapoor; Edward Matsumoto; Jean-Baptiste Lattouf; Fred Saad; Louis Lacombe; Yves Fradet; Adrian Fairey; Niels-Eric Jacobson; Darryl Drachenberg; Ilias Cagiannos; Alan So; Peter Black
Journal:  Can Urol Assoc J       Date:  2012-12       Impact factor: 1.862

5.  Clinical intervals and diagnostic characteristics in a cohort of prostate cancer patients in Spain: a multicentre observational study.

Authors:  Xavier Bonfill; María José Martinez-Zapata; Robin W M Vernooij; María José Sánchez; María Morales Suárez-Varela; Javier de la Cruz; José Ignacio Emparanza; Montserrat Ferrer; José Ignacio Pijoán; Juan M Ramos-Goñi; Joan Palou; Stefanie Schmidt; Víctor Abraira; Javier Zamora
Journal:  BMC Urol       Date:  2015-07-02       Impact factor: 2.264

6.  Clinical interval and diagnostic characteristics in a cohort of bladder cancer patients in Spain: a multicenter observational study.

Authors:  Xavier Bonfill; María José Martinez-Zapata; Robin W M Vernooij; María José Sánchez; María Morales Suárez-Varela; Javier De la Cruz; José Ignacio Emparanza; Montserrat Ferrer; José Ignacio Pijoan; Joan Palou; Stefanie Schmidt; Eva Madrid; Víctor Abraira; Javier Zamora
Journal:  BMC Res Notes       Date:  2017-12-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.